Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OSSIO Raises $27.6M Equity Financing
Financial/Business

OSSIO Raises $27.6M Equity Financing to Speed Commercial Engine

This includes a new product pipeline, sales channel, and medical education, as well as building a flagship U.S. manufacturing site and surgeon training center in Florida.

OSSIO recently closed on $27.6 million in equity funding in order to quickly scale all aspects of its commercial efforts.

This includes a new product pipeline, sales channel, and medical education, as well as building a flagship U.S. manufacturing site and surgeon training center in Florida.

The company’s OSSIOfiber implants offer strong fixation while leaving nothing permanent behind, avoiding the risk of common post-surgical complications and secondary procedures related to metal and similar materials. After serving their fixation function, the implants integrate and are replaced with natural bone.

Questa Capital led this latest round of financing with participation from existing investors MVM Partners, OCV, Ortho-Vision, and Courage Capital.

“This new investment in OSSIO strengthens our ability to build upon our proven claim as the most innovative and differentiated implant technology to enter the $16 billion orthopedic fixation market,” said OSSIO CEO Brian Verrier. “The additional funding will enable us to accelerate our commercial footprint and the adoption of OSSIOfiber implants in the United States and select international markets. Specifically, we are already expanding our OSSIO sales team to strengthen the support of our distribution partners and customers, as well as securing the needed manufacturing capacity for several years of future growth.”

Since OSSIO’s first product launch in 2019, over 50,000 OSSIOfiber implants have been used in a variety of orthopedic procedures. Last month, the company debuted its OSSIOfiber threaded trimmable fixation nail for extremity fracture fixation.

“OSSIO fits squarely into our investment strategy,” said Ryan Drant, Founder and Managing Partner of Questa Capital. “The company is growing rapidly and has established OSSIOfiber implants as a differentiated and disruptive medical technology with clear patient benefits and passionate surgeon users. We are pleased to support OSSIO’s efforts to evolve the practice of orthopedic surgery.”

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters